Skip to main content
. 2017 Oct 17;8(61):103274–103282. doi: 10.18632/oncotarget.21870

Figure 1. Kaplan-Meier analysis of disease progression.

Figure 1

CMML patients with MF1+ showed a shorter progression-free survival (28.3 months vs not reached, p = 0.001 log rank test) compared to MF-0 patients (left). No difference was observed in the median overall survival (MF-0: 48.3 vs MF1+:41,7 months, p = 0.1) between these two groups (right).